Small Fiber Polyneuropathy Is Prevalent in Patients Experiencing Complex Chronic Pelvic Pain

• Published in: Pain medicine (Malden, Mass.) Vol. 20; no. 3; pp. 521 - 527
• Main Authors: Chen, Annie, De, Elise, Argoff, Charles
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.03.2019
• Subjects: Analgesics; Chronic pain; Comorbidity; Complications and side effects; Cystitis; Diagnosis; Endometriosis; Fibromyalgia; Gastroesophageal reflux; Headache; Immunoglobulins; Immunomodulation; Intestine; Intravenous administration; Irritable bowel syndrome; Lidocaine; Low back pain; Medical diagnosis; Migraine; Pain; Pain management; Pelvic pain; Pelvis; Polyneuropathies; Polyneuropathy; Risk factors; Statistics; United States; Refractory; Skin Punch Biopsy; Epidermal Nerve Fiber Density; Pelvic Pain; Small Fiber Polyneuropathy
• ISSN: 1526-2375; 1526-4637; 1526-4637
• DOI: 10.1093/pm/pny001

Abstract Objective To demonstrate the prevalence of small fiber polyneuropathy (SFPN) in patients with refractory chronic pelvic pain (CPP). Design Retrospective study of prospective database. Subjects Participants were complex CPP patients recruited from subspecity referral clinics defined as those who were refractory to initial treatment and/or exhibited comorbid pain syndromes at initial presentation. Methods Comprehensive treatment history for CPP was obtained, and participants referred as above; 3-mm punch biopsies were obtained of the lower extremity and sent to diagnostic reference labs to evaluate for SFPN. The reported lab sensitivity and specificity for SFPN are 78–92% and 65–90%, respectively. Results Twenty-five of 39 patients (64%) were positive for SFPN. Comorbid conditions noted in our population included gastroesophageal reflux disease (46%), migraine (38%), irritable bowel syndrome (33%), lower back pain (33%), fibromyalgia (38%), endometriosis (15%), interstitial cystitis (18%), vulvodynia (5%), and other chronic pain syndromes (36%). Conclusions The prevalence of SFPN in our specialty referral patients with complex CPP is remarkably high vs published general population prevalence data (53/100,000). Identification of SFPN in this complex population shifts the focus from undefined syndromes to symptom complexes with linked potentially treatable mechanisms (e.g., SFPN, central sensitization). Most CPP patients with SFPN are undiagnosed. Considering the diagnosis may expand treatment options beyond conventional or so-called adjuvant analgesics. Treatment may expand to therapies such as IV lidocaine, IVIG, or other immunomodulatory options. In addition, the value to the patient of receiving a diagnosis for a multisystem or refractory pain syndrome, often attributed to negative psychologic factors, cannot be underestimated. Identifying SFPN should be contemplated in CPP patients who present with multisystem pain or who have not responded to initial evaluation and management.